Mperia Therapeutics Inc. Appoints Dr Christian Weber to Clinical Advisory Board
MONTREAL--(BUSINESS WIRE)--Feb 28, 2019--Christian Weber, PhD, MD, Chair of Preventative Vascular Medicine and Director of the Institute for Cardiovascular Prevention at Ludwig‐Maximilians University (LMU) Munich, Germany, joins the Clinical Advisory Board (CAB) of Mperia Therapeutics Inc.
“Dr Weber is that rarity: an eminent practicing cardio-vascular clinician who also has unparalleled research experience and has published key papers directly related to macrophage recruitment and involvement in atherosclerosis. Additionally, our mutual interest in peptides and peptido-mimetics as pharmaceutical candidates represents an optimal appointment for Mperia,” says CEO and President Paul Chipperton.
Christian Weber, MD, PhD. After graduating and completing his training in internal medicine at LMU, Munich and Harvard Medical School, Boston, Dr. Weber was board‐certified in clinical cardiology and appointed as Chair in Molecular Cardiology at RWTH Aachen University. His group has a strong interest in the molecular interactions and pathophysiological functions of chemokines and immune cell subsets, as well as in the role of microRNAs and their targets in vascular disease, namely atherosclerosis. As for his clinical interests, he focuses on developing novel biomarkers and peptide-based biopharmaceuticals.
Dr. Weber is the Spokesman of the DFG Collaborative Research Centre SFB1123 and coordinates the partner site Munich Heart Alliance in the German Centre for Cardiovascular Research (DZHK). Among many other awards, he is a VICI laureate and double ERC Advanced Investigator Grant recipient with more than 560 publications and an h‐index of 96. He serves as the Editor‐in‐Chief of Thrombosis & Haemostasis, Senior Associate Editor of Arteriosclerosis, Thrombosis & Vascular Biology and is the co‐founder of Carolus Therapeutics Inc.
ABOUT MPERIA THERAPEUTICS INC.
Mperia Therapeutics is The CD36 Therapeutics Company focusing on macrophage-driven inflammation. The technology exploits CD36-targeting cyclic peptides and their capacity to impact the cell inflammasome and modify macrophages’ metabolic dysfunction, resulting in outstanding anti-inflammatory response. Mperia holds exclusive rights to several highly-efficacious CD36 receptor ligands to be used in dry AMD, atherosclerosis and NASH.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190228005553/en/
Paul Chipperton, BSc, MBA
CEO & President – Mperia Therapeutics Inc.
E:firstname.lastname@example.orgElizabeth Douville, Ph.D.
Co-founder and Managing Partner, AmorChem
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY
SOURCE: Mperia Therapeutics Inc.
Copyright Business Wire 2019.
PUB: 02/28/2019 10:00 AM/DISC: 02/28/2019 10:01 AM